What is 'food noise' and why do GLP-1 medications reduce it?

Food noise refers to the persistent, background mental preoccupation with food — intrusive thoughts about eating, planning the next meal, or being unable to stop thinking about certain foods. Some people experience this as nearly continuous. GLP-1 receptor agonists appear to reduce food noise by acting on GLP-1 receptors in the central nervous system, particularly in the hypothalamus and areas involved in reward processing. The effect is not simply 'less hungry' — it is closer to the absence of a chronic mental signal, which patients often describe as qualitatively different from anything dietary restriction has achieved. Not all users experience this effect to the same degree.

What side effects should I know about before starting a GLP-1 medication?

The most common side effects are gastrointestinal: nausea, vomiting, diarrhoea, and constipation. These are most pronounced during dose escalation — when the dose is being increased over weeks to months — and tend to reduce once a stable dose is reached. Eating smaller meals, avoiding high-fat foods, and not eating immediately before lying down can reduce nausea. Rare but serious side effects include pancreatitis and, in animal studies, certain thyroid tumours — these are reasons why the medications are contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia. Your GP will review your suitability before prescribing, and should counsel you on what to expect so you can identify side effects early rather than after weeks of discomfort.

GLP-1 medications and 'food noise': what patients actually say

What just happened

A qualitative study published this month in JAMA Network Open interviewed 30 people currently using or recently using GLP-1 receptor agonist (GLP-1 RA) medications — semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro), and related agents — about their direct experience of treatment.

Thirty participants from 15 US states. Twenty-three were currently using a GLP-1 RA at time of interview; seven had previously used one and stopped. Interviews were conducted between July and September 2025.

RACGP newsGP covered the study this week, reporting eight key themes from the qualitative analysis. Two emerged most prominently: that these medications reduce what participants called “food noise,” and that the quality of clinical support patients received was highly variable — and in many cases inadequate.

The both-and

GLP-1 medications are genuinely changing how people experience appetite and eating. The clinical infrastructure to support patients on these medications is not consistently keeping pace.

What patients said about food noise

“Food noise” — the persistent, background mental preoccupation with food that many people with obesity describe as nearly continuous — was the dominant experience that participants reached for when describing what these medications had changed.

For many, GLP-1 receptor agonists appeared to reduce or largely eliminate this experience in a way that dietary restriction, willpower, and previous weight-loss attempts had not. The effect was described not as “less hungry” in the conventional sense, but as something more fundamental: the quieting of a chronic mental signal.

From a clinical standpoint, this effect is biologically plausible. GLP-1 receptors are expressed throughout the central nervous system, including in the hypothalamus and in reward-processing circuits. GLP-1 agonists appear to reduce the salience — the urgency and pull — of food cues, not just the physiological sensation of hunger. The difference between “less hungry” and “food is quieter in my mind” is clinically meaningful: the latter suggests an effect on reward pathway function rather than purely on satiety signalling.

For patients who have spent years managing what they experience as an overwhelming drive toward eating, this effect is described as genuinely transformative. It is also, as participants consistently noted, insufficient on its own.

What patients said about clinical support

The findings on care quality are less comfortable. The study found that “the quality of care for each patient was ‘highly variable’” — and in many cases fell short of what a new medication class with a known adverse-effect profile and a complex behavioural context requires.

Specific patterns from participant accounts:

One participant experienced vomiting and diarrhoea for several weeks without recognising these as medication side effects — because adequate counselling about what to expect had not been provided. This is a direct clinical failure with a simple fix: counselling about the expected side-effect trajectory, particularly during dose escalation, is basic prescribing practice.

Clinical encounters were frequently described as “brief and transactional” — a prescription written with little opportunity to ask questions, discuss the experience, or plan for difficulties. Some participants went weeks after initiating a new medication with no follow-up from the prescribing clinician.

Access was also inequitable. The cost of these medications — running to several hundred dollars per month without subsidy — meant that some participants were managing on doses they could afford rather than doses that were clinically appropriate.

GLP-1 medications as tools, not solutions

The third theme worth naming: participants across the study consistently framed GLP-1 medications as supportive tools rather than replacements for personal effort. The medications quieted food noise and reduced appetite. Participants still had to make choices about what to eat, how to move, how to manage the psychological relationship with food that had driven eating patterns over years.

This aligns with what the clinical evidence supports. These medications are adjuncts to a broader behavioural programme — they are not standalone weight-loss interventions, and their long-term effects depend substantially on what else is in place. When patients understand this from the outset, outcomes are likely better than when the medication is provided without that framing.

2 cents

This study is US-based, and Australian prescribing pathways differ — GLP-1 RAs are available here through PBS subsidy for specific indications including type 2 diabetes, and increasingly via private prescription for weight management. The clinical experience described in the study is not a direct mirror of Australian general practice. But the underlying issue is generalisable: these medications require more clinical infrastructure than a brief consultation and a repeat script.

If you are using a GLP-1 medication and the support around that looks like a vending machine — prescription on request, minimal follow-up, no discussion of what to expect — that is worth naming with your GP.

Specifically: you should know, before the first dose, what the common side effects are and what trajectory to expect (nausea typically peaks during dose escalation and improves). You should have a clear understanding of what the medication is and is not doing — it is a support for behaviour change, not a replacement for it. And you should have a plan for what happens if side effects are intolerable or if the medication stops working.

If you are considering a GLP-1 medication and want to understand whether it might be appropriate for your situation, that conversation belongs with your GP, who can review your clinical history, current medications, and specific context.

This is general health information and does not constitute individual clinical advice.

Verdict

Verdict: yes — worth knowing about.

The food noise finding is clinically valuable: it gives patients and GPs a shared vocabulary for an effect that is real, partially distinct from simple appetite suppression, and important for understanding why these medications feel qualitatively different to those who respond to them. The care quality finding is a direct prompt: a GLP-1 prescription without adequate counselling, realistic expectations, and follow-up is less effective and less safe than one with them. Both are actionable this week.